Overview
Blueprint Biosecurity is a non-profit organization that identifies gaps in pandemic preparedness and creates actionable roadmaps to develop and deploy biosecurity technologies and policies. It funds research, publishes reports, and provides strategic guidance, then partners with government, academia, industry, and philanthropy to implement these plans. Its programs focus on airborne-pathogen suppression technologies (such as Far-UVC), low-cost air disinfection (glycol vapors), and improved PPE like reusable respirators. Its goal is to reduce global risk from airborne diseases by accelerating adoption of validated solutions and strengthening preparedness through coordinated research and policy advocacy.
Work here?Claim your company
Simplify's take
What believers are saying
- 2026 brought nearly $4.5 million in GlycolISER awards across seven grantees.
- Blueprint funded far-UVC protocols, with RCT designs targeted for fall 2026.
- Open 2026 RFPs for pathogen detection and SAFE-UVC keep partner demand visible.
What critics are saying
- Far-UVC still lacks real-world efficacy proof; deployment depends on late-2026 trial results.
- Glycol vapors face safety and air-quality scrutiny, especially University of Iowa asthma studies.
- If EPA and grantees underdeliver, Blueprint becomes a niche think tank without product moat.
What makes Blueprint Biosecurity unique
- Blueprint Biosecurity pairs policy advocacy with grantmaking on far-UVC, glycol vapors, and respirators.
- Its 2026 EPA CRADA gives direct access to the Aerosol Test Facility.
- The Bioresilience Fund finances concrete research roadmaps and public outputs.
Help us improve and share your feedback! Did you find this helpful?